Overview

Phase 2b/3 Study to Assess Efficacy and Safety of ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

Treatments:

Allopurinol